MA42160A - Procédés de culture de cellules in vitro pour la beta-thalassemie a l'aide de pieges a ligands du recepteur de l'activine de type ii - Google Patents
Procédés de culture de cellules in vitro pour la beta-thalassemie a l'aide de pieges a ligands du recepteur de l'activine de type iiInfo
- Publication number
- MA42160A MA42160A MA042160A MA42160A MA42160A MA 42160 A MA42160 A MA 42160A MA 042160 A MA042160 A MA 042160A MA 42160 A MA42160 A MA 42160A MA 42160 A MA42160 A MA 42160A
- Authority
- MA
- Morocco
- Prior art keywords
- thalassemia
- cell culture
- beta
- receptor ligand
- vitro cell
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0641—Erythrocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/18—Erythrocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/025—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/483—Physical analysis of biological material
- G01N33/4833—Physical analysis of biological material of solid biological material, e.g. tissue samples, cell cultures
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/16—Activin; Inhibin; Mullerian inhibiting substance
Abstract
La présente invention concerne des procédés de traitement de la bêta-thalassémie chez un sujet comprenant l'administration d'un inhibiteur de signalisation du récepteur d'actine ii (actrii) (par exemple, un piège à ligand activine) et l'utilisation d'une ou plusieurs méthodes de culture cellulaire in vitro. ) sélection du sujet à traiter selon les méthodes fournies ici; et / ou (ii) la surveillance du sujet traité selon les méthodes fournies ici.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562164367P | 2015-05-20 | 2015-05-20 | |
US201662320032P | 2016-04-08 | 2016-04-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA42160A true MA42160A (fr) | 2018-03-28 |
Family
ID=57320751
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA042160A MA42160A (fr) | 2015-05-20 | 2016-05-19 | Procédés de culture de cellules in vitro pour la beta-thalassemie a l'aide de pieges a ligands du recepteur de l'activine de type ii |
Country Status (8)
Country | Link |
---|---|
US (2) | US10548976B2 (fr) |
EP (2) | EP3298034A4 (fr) |
JP (2) | JP2018522579A (fr) |
CN (1) | CN108350057A (fr) |
CA (1) | CA2986432A1 (fr) |
HK (1) | HK1252174A1 (fr) |
MA (1) | MA42160A (fr) |
WO (1) | WO2016187378A1 (fr) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014071158A1 (fr) | 2012-11-02 | 2014-05-08 | Celgene Corporation | Antagonistes d'activine-actrii et utilisations pour le traitement de troubles osseux et autres |
MA41052A (fr) | 2014-10-09 | 2017-08-15 | Celgene Corp | Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii |
ES2946160T3 (es) | 2014-12-03 | 2023-07-13 | Celgene Corp | Antagonistas de activina-ActRII y usos para tratar síndrome mielodisplásico |
CA2986432A1 (fr) | 2015-05-20 | 2016-11-24 | Celgene Corporation | Procedes de culture de cellules in vitro pour la beta-thalassemie a l'aide de pieges a ligands du recepteur de l'activine de type ii |
US11123430B2 (en) | 2015-11-04 | 2021-09-21 | Acceleron Pharma Inc. | Methods for increasing red blood cell levels and treating ineffective erythropoiesis |
US11013785B2 (en) | 2016-11-10 | 2021-05-25 | Keros Therapeutics, Inc. | Activin receptor type IIA variants and methods of use thereof |
EP3567096A4 (fr) * | 2017-01-06 | 2020-10-21 | Olympus Corporation | Système d'observation de cellules |
WO2019094751A1 (fr) | 2017-11-09 | 2019-05-16 | Keros Therapeutics, Inc. | Variants de type iia du récepteur de l'activine et leurs méthodes d'utilisation |
JP2021518745A (ja) | 2018-01-12 | 2021-08-05 | ケロス セラピューティクス インコーポレイテッドKeros Therapeutics,Inc. | アクチビンiib型受容体変異体およびそれらの使用方法 |
AU2019266314A1 (en) * | 2018-05-09 | 2020-11-19 | Keros Therapeutics, Inc. | Activin receptor type iia variants and methods of use thereof |
JP7388679B2 (ja) * | 2019-05-28 | 2023-11-29 | 学校法人 東洋大学 | 熱中症マーカー及びその利用 |
AU2021237730A1 (en) * | 2020-03-20 | 2022-10-06 | Keros Therapeutics, Inc. | Activin receptor type II chimeras and methods of use thereof |
CA3176701A1 (fr) * | 2020-04-28 | 2021-11-04 | Gang Li | Proteines actrii et leur utilisation dans le traitement de l'hypertension pulmonaire post-capillaire |
WO2022098877A1 (fr) * | 2020-11-06 | 2022-05-12 | Acceleron Pharma Inc. | Formulations comprenant des variants polypeptidiques actrii |
Family Cites Families (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2338405T3 (es) * | 1999-02-04 | 2010-05-07 | Pluristem Ltd. | Metodo y aparato para mantenimiento y expasion de celulas madre hemopoyeticas y/o celulas progenitoras. |
JP2004526419A (ja) | 2000-10-16 | 2004-09-02 | フィロス インク. | 抗体模倣物および他の結合タンパク質のためのタンパク質骨格 |
US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
WO2002088171A2 (fr) | 2001-04-26 | 2002-11-07 | Avidia Research Institute | Banques combinatoires de domaines monomeres |
DK2332977T3 (en) | 2004-07-23 | 2016-02-29 | Acceleron Pharma Inc | ActRII receptor polypeptides |
MX2007005884A (es) | 2004-11-16 | 2008-02-12 | Amgen Mountain View Inc | Andamios de proteina y usos de los mismos. |
CA3045808C (fr) | 2005-11-23 | 2022-08-16 | Acceleron Pharma, Inc. | Antagonistes de l'activine-actriia et utilisations pour activer la croissance osseuse |
US20100028332A1 (en) | 2006-12-18 | 2010-02-04 | Acceleron Pharma Inc. | Antagonists of actriib and uses for increasing red blood cell levels |
CN104524548A (zh) | 2006-12-18 | 2015-04-22 | 阿塞勒隆制药公司 | 活化素-actrii拮抗剂及在提高红细胞水平中的用途 |
US8895016B2 (en) | 2006-12-18 | 2014-11-25 | Acceleron Pharma, Inc. | Antagonists of activin-actriia and uses for increasing red blood cell levels |
ES2415666T3 (es) | 2007-02-01 | 2013-07-26 | Acceleron Pharma, Inc. | Composiciones farmacéuticas que comprenden antagonistas de Activina-ActRIIa para uso en la prevención o el tratamiento de metástasis de cáncer de mama o pérdida ósea relacionada con el cáncer de mama |
TW201907946A (zh) | 2007-02-02 | 2019-03-01 | 美商艾瑟勒朗法瑪公司 | 衍生自ActRIIB的變體與其用途 |
EP2484372A1 (fr) | 2007-02-09 | 2012-08-08 | Acceleron Pharma, Inc. | Antagonistes de L'Activine-ActRIIa et Utilisations pour la Promotion de la Croissance Osseuse Chez Les Patients Cancereux |
CA2699936A1 (fr) | 2007-09-18 | 2009-03-26 | Acceleron Pharma Inc. | Antagonistes de l'activine-actriia et utilisations pour reduire ou empecher la secretion de fsh |
WO2009158025A2 (fr) | 2008-06-26 | 2009-12-30 | Acceleron Pharma Inc. | Procédés pour administrer un antagoniste d’actriib et surveiller des patients traités |
US8216997B2 (en) | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
HRP20230761T1 (hr) | 2008-08-14 | 2023-10-13 | Acceleron Pharma Inc. | Gdf zamke |
US8138142B2 (en) | 2009-01-13 | 2012-03-20 | Acceleron Pharma Inc. | Methods for increasing adiponectin in a patient in need thereof |
AU2010258931B2 (en) | 2009-06-08 | 2015-04-23 | Acceleron Pharma Inc. | Methods for increasing thermogenic adipocytes |
US8293881B2 (en) | 2009-06-12 | 2012-10-23 | Acceleron Pharma Inc. | Isolated nucleic acid encoding a truncated ActRIIB fusion protein |
IL287990B (en) | 2009-08-13 | 2022-07-01 | Acceleron Pharma Inc | Combined use of gdf traps and erythropoietin receptor activators to increase red blood cell levels |
CN102781518A (zh) | 2009-09-09 | 2012-11-14 | 阿塞勒隆制药公司 | Actriib拮抗剂及其给药和用途 |
WO2011056896A1 (fr) | 2009-11-03 | 2011-05-12 | Acceleron Pharma Inc. | Procédés de traitement de la stéatose hépatique |
ES2658292T3 (es) | 2009-11-17 | 2018-03-09 | Acceleron Pharma, Inc. | Proteínas ActRIIB y variantes y usos de las mismas con respecto a la inducción de la utrofina para el tratamiento de la distrofia muscular |
CA2852683A1 (fr) | 2011-10-17 | 2013-04-25 | Acceleron Pharma, Inc. | Methodes et compositions destinees au traitement d'une erythropoiese inefficace |
ES2753811T3 (es) | 2012-10-24 | 2020-04-14 | Celgene Corp | Biomarcador para uso en el tratamiento de anemia |
CN112957462A (zh) | 2012-10-24 | 2021-06-15 | 细胞基因公司 | 用于治疗贫血的方法 |
WO2014071158A1 (fr) | 2012-11-02 | 2014-05-08 | Celgene Corporation | Antagonistes d'activine-actrii et utilisations pour le traitement de troubles osseux et autres |
EP3808778A1 (fr) | 2014-04-18 | 2021-04-21 | Acceleron Pharma Inc. | Procédés d'augmentation des taux de globules rouges et de traitement de la drépanocytose |
CA2951926C (fr) | 2014-06-13 | 2023-01-10 | Acceleron Pharma, Inc. | Methodes et compositions de traitement d'ulceres |
MA41052A (fr) | 2014-10-09 | 2017-08-15 | Celgene Corp | Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii |
ES2946160T3 (es) | 2014-12-03 | 2023-07-13 | Celgene Corp | Antagonistas de activina-ActRII y usos para tratar síndrome mielodisplásico |
MA41119A (fr) | 2014-12-03 | 2017-10-10 | Acceleron Pharma Inc | Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique |
JP6976859B2 (ja) | 2015-05-13 | 2021-12-08 | セルジーン コーポレイション | ActRIIリガンドトラップを用いたβ−サラセミアの治療 |
CA2986432A1 (fr) | 2015-05-20 | 2016-11-24 | Celgene Corporation | Procedes de culture de cellules in vitro pour la beta-thalassemie a l'aide de pieges a ligands du recepteur de l'activine de type ii |
US11123430B2 (en) | 2015-11-04 | 2021-09-21 | Acceleron Pharma Inc. | Methods for increasing red blood cell levels and treating ineffective erythropoiesis |
EP3380121B1 (fr) | 2015-11-23 | 2023-12-20 | Acceleron Pharma Inc. | Actrii antagoniste pour l'utilisation dans le traitement des troubles oculaires |
RS62011B1 (sr) | 2016-07-15 | 2021-07-30 | Acceleron Pharma Inc | Kompozicije koje sadrže polipeptide actriia za upotrebu u lečenju plućne hipertenzije |
KR20190040972A (ko) | 2016-07-27 | 2019-04-19 | 악셀레론 파마 인코포레이티드 | 골섬유증 치료 방법 및 조성물 |
US20200101134A1 (en) | 2017-06-14 | 2020-04-02 | Celgene Corporation | Methods for treating myeloproliferative neoplasm-associated myelofibrosis and anemia |
-
2016
- 2016-05-19 CA CA2986432A patent/CA2986432A1/fr active Pending
- 2016-05-19 EP EP16797267.8A patent/EP3298034A4/fr not_active Withdrawn
- 2016-05-19 MA MA042160A patent/MA42160A/fr unknown
- 2016-05-19 WO PCT/US2016/033187 patent/WO2016187378A1/fr active Application Filing
- 2016-05-19 CN CN201680042691.9A patent/CN108350057A/zh active Pending
- 2016-05-19 JP JP2018512825A patent/JP2018522579A/ja active Pending
- 2016-05-19 US US15/574,897 patent/US10548976B2/en not_active Expired - Fee Related
- 2016-05-19 EP EP22201847.5A patent/EP4190805A3/fr not_active Withdrawn
-
2018
- 2018-09-07 HK HK18111575.0A patent/HK1252174A1/zh unknown
-
2019
- 2019-12-11 US US16/711,039 patent/US20200101157A1/en not_active Abandoned
-
2021
- 2021-09-29 JP JP2021158571A patent/JP2022023072A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3298034A4 (fr) | 2019-02-13 |
HK1252174A1 (zh) | 2019-05-17 |
US10548976B2 (en) | 2020-02-04 |
US20200101157A1 (en) | 2020-04-02 |
CA2986432A1 (fr) | 2016-11-24 |
CN108350057A (zh) | 2018-07-31 |
JP2018522579A (ja) | 2018-08-16 |
JP2022023072A (ja) | 2022-02-07 |
US20180161426A1 (en) | 2018-06-14 |
EP4190805A3 (fr) | 2023-08-16 |
EP4190805A2 (fr) | 2023-06-07 |
WO2016187378A1 (fr) | 2016-11-24 |
EP3298034A1 (fr) | 2018-03-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA42160A (fr) | Procédés de culture de cellules in vitro pour la beta-thalassemie a l'aide de pieges a ligands du recepteur de l'activine de type ii | |
MA43335B1 (fr) | Compositions d'arni de transthyrétine (ttr) et procédés pour les utiliser pour le traitement ou la prévention de maladies associées à ttr | |
MA41013A (fr) | Compositions comprenant des souches bactériennes | |
MA40843A (fr) | Compositions d'arni contre le virus de l'hépatite delta et procédés d'utilisation de celles-ci | |
MA40132A1 (fr) | Inhibiteurs macrocycliques des interactions protéine/protéine pd-1/pd-l1 et cd80(b7-1)/pd-li | |
EA201992546A1 (ru) | Средства на основе антител к cd33 | |
MA40682B1 (fr) | Anticorps anti-ox40 et procédés d'utilisation correspondants | |
MA46836A (fr) | Agents, utilisations et procédés pour le traitement d'une synucléinopathie | |
MA40768A (fr) | Dérivés d'indole mono ou di-substitué en tant qu'inhibiteurs de réplication du virus de la dengue | |
MA42439A (fr) | Agents, utilisations et procédés pour le traitement d'une synucléinopathie | |
MA34002B1 (fr) | Thérapie antivirale | |
MA42811A (fr) | Dérivés d'indole monosubstitués ou disubstitués utilisés en tant qu'inhibiteurs de la réplication du virus de la dengue | |
MA39248B1 (fr) | Anticorps anti-jagged1 et procédés d'utilisation correspondants | |
FR3021970B1 (fr) | Anticorps dirige contre la galectine 9 et inhibiteur de l'activite suppressive des lymphocytes t regulateurs | |
MA43763B1 (fr) | Protéine f de pré-fusion du vrs soluble et stabilisée pour son utilisation dans la prophylaxie d'une infection vrs | |
MA51306A (fr) | Compositions et procédés améliorés pour le traitement du déficit en ornithine transcarbamylase | |
EA201791614A1 (ru) | Производные индола в качестве ингибиторов репликации вирусов денге | |
MA43113A (fr) | Anticorps anti-htr a1 et méthodes d'utilisation de ceux-ci | |
MA40283A (fr) | Aptamères spécifiques du récepteur tlr-4 et leurs utilisations | |
MA46548A (fr) | Fsh pour le traitement de l'infertilité | |
EA201892287A1 (ru) | Фармацевтические комбинации для лечения рака | |
FR3045834B1 (fr) | Diluant de reactifs pour immunoessai | |
MA38253A1 (fr) | Compositions comprenant de la vortioxétine et du donépézil | |
ATE464911T1 (de) | Zusammensetzungen zur behandlung von systemischer mastocytose | |
MA39336A1 (fr) | Molécules d'anticorps anti-lag-3 et leurs utilisations |